Stifel Financial Corp Has $195,000 Stake in AbCellera Biologics Inc. (NASDAQ:ABCL)

Stifel Financial Corp cut its position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL) by 26.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 74,814 shares of the company’s stock after selling 27,563 shares during the quarter. Stifel Financial Corp’s holdings in AbCellera Biologics were worth $195,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of ABCL. Arcadia Investment Management Corp MI bought a new stake in AbCellera Biologics during the third quarter valued at $26,000. NBC Securities Inc. lifted its stake in shares of AbCellera Biologics by 56.0% in the 3rd quarter. NBC Securities Inc. now owns 11,420 shares of the company’s stock valued at $29,000 after purchasing an additional 4,100 shares during the period. Evergreen Capital Management LLC bought a new stake in shares of AbCellera Biologics during the 2nd quarter valued at about $32,000. Ballentine Partners LLC bought a new stake in shares of AbCellera Biologics during the 3rd quarter valued at about $54,000. Finally, Clarkston Capital Partners LLC acquired a new stake in AbCellera Biologics during the third quarter worth approximately $57,000. Institutional investors own 61.42% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on ABCL shares. Benchmark reissued a “hold” rating on shares of AbCellera Biologics in a research note on Tuesday, November 5th. Stifel Nicolaus reiterated a “buy” rating and set a $12.00 target price (down previously from $14.00) on shares of AbCellera Biologics in a research report on Tuesday, November 5th.

AbCellera Biologics Price Performance

Shares of ABCL opened at $2.82 on Tuesday. AbCellera Biologics Inc. has a one year low of $2.34 and a one year high of $6.05. The company has a market cap of $832.93 million, a PE ratio of -4.62 and a beta of 0.41. The stock has a 50-day moving average of $2.85 and a 200-day moving average of $2.79.

AbCellera Biologics (NASDAQ:ABCL) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The firm had revenue of $6.51 million during the quarter, compared to analyst estimates of $8.95 million. AbCellera Biologics had a negative net margin of 533.32% and a negative return on equity of 15.73%. During the same period last year, the business posted ($0.10) EPS. Analysts expect that AbCellera Biologics Inc. will post -0.59 EPS for the current fiscal year.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.